Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.18
CTIC's Cash to Debt is ranked higher than
60% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CTIC: 2.18 )
CTIC' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 2.18

Equity to Asset 0.28
CTIC's Equity to Asset is ranked higher than
55% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CTIC: 0.28 )
CTIC' s 10-Year Equity to Asset Range
Min: -19.51   Max: 0.95
Current: 0.28

-19.51
0.95
F-Score: 6
Z-Score: -35.52
M-Score: 32.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -48.59
CTIC's Operating margin (%) is ranked higher than
76% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. CTIC: -48.59 )
CTIC' s 10-Year Operating margin (%) Range
Min: -123250   Max: -119.75
Current: -48.59

-123250
-119.75
Net-margin (%) -55.34
CTIC's Net-margin (%) is ranked higher than
75% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CTIC: -55.34 )
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75   Max: -123.26
Current: -55.34

-169773.75
-123.26
ROE (%) -204.07
CTIC's ROE (%) is ranked higher than
53% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. CTIC: -204.07 )
CTIC' s 10-Year ROE (%) Range
Min: -107.23   Max: -42.02
Current: -204.07

-107.23
-42.02
ROA (%) -61.52
CTIC's ROA (%) is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. CTIC: -61.52 )
CTIC' s 10-Year ROA (%) Range
Min: -261.37   Max: -20.35
Current: -61.52

-261.37
-20.35
ROC (Joel Greenblatt) (%) -621.47
CTIC's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. CTIC: -621.47 )
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2180.72   Max: -48.38
Current: -621.47

-2180.72
-48.38
Revenue Growth (%) 210.70
CTIC's Revenue Growth (%) is ranked higher than
100% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CTIC: 210.70 )
CTIC' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 329.2
Current: 210.7

-100
329.2
EBITDA Growth (%) -52.90
CTIC's EBITDA Growth (%) is ranked higher than
53% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CTIC: -52.90 )
CTIC' s 10-Year EBITDA Growth (%) Range
Min: -71   Max: 50.1
Current: -52.9

-71
50.1
EPS Growth (%) -59.50
CTIC's EPS Growth (%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CTIC: -59.50 )
CTIC' s 10-Year EPS Growth (%) Range
Min: -74.4   Max: 64
Current: -59.5

-74.4
64
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CTIC Guru Trades in Q4 2013

Jim Simons 285,747 sh (New)
» More
Q1 2014

CTIC Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

CTIC Guru Trades in Q2 2014

Jim Simons 692,650 sh (New)
» More
Q3 2014

CTIC Guru Trades in Q3 2014

Jim Simons 1,010,871 sh (+45.94%)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about CTI Biopharma Corp

Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar General Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp. and Dollar General Corp. Read more...

Ratios

vs
industry
vs
history
P/B 18.20
CTIC's P/B is ranked higher than
60% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. CTIC: 18.20 )
CTIC' s 10-Year P/B Range
Min: 1.52   Max: 122
Current: 18.2

1.52
122
P/S 4.40
CTIC's P/S is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. CTIC: 4.40 )
CTIC' s 10-Year P/S Range
Min: 0.01   Max: 288
Current: 4.4

0.01
288
EV-to-EBIT -9.17
CTIC's EV-to-EBIT is ranked higher than
53% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CTIC: -9.17 )
CTIC' s 10-Year EV-to-EBIT Range
Min: -11.2   Max: 0.4
Current: -9.17

-11.2
0.4
Current Ratio 1.94
CTIC's Current Ratio is ranked higher than
59% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CTIC: 1.94 )
CTIC' s 10-Year Current Ratio Range
Min: 0.38   Max: 24.99
Current: 1.94

0.38
24.99
Quick Ratio 1.78
CTIC's Quick Ratio is ranked higher than
60% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CTIC: 1.78 )
CTIC' s 10-Year Quick Ratio Range
Min: 0.38   Max: 24.96
Current: 1.78

0.38
24.96

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.15
CTIC's Price/Tangible Book is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. CTIC: 18.15 )
CTIC' s 10-Year Price/Tangible Book Range
Min: 0.15   Max: 1492
Current: 18.15

0.15
1492
Price/Median PS Value 0.49
CTIC's Price/Median PS Value is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CTIC: 0.49 )
CTIC' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 15849.02
Current: 0.49

0.01
15849.02
Earnings Yield (Greenblatt) -10.90
CTIC's Earnings Yield (Greenblatt) is ranked higher than
67% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CTIC: -10.90 )
CTIC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 270.8   Max: 4002.2
Current: -10.9

270.8
4002.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0QUJ.UK, CTIC.Italy, CEPR.Germany,
CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May 2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies.The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
comment on CTIC Dec 16 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BIOPHARMA CORP Files SEC form 8-K, Other Events Dec 11 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 09 2014
CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated... Dec 09 2014
CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated... Dec 09 2014
CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases... Dec 06 2014
CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases... Dec 06 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 04 2014
CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX® Dec 04 2014
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off Dec 02 2014
CTI BioPharma Announces Data Presentations at the 56th American Society of Hematology Annual Meeting Dec 01 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Nov 26 2014
CTI BioPharma to Present at the Upcoming Investor Conferences Nov 17 2014
CTI BioPharma to Present at the Upcoming Investor Conferences Nov 17 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Nov 13 2014
CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock Nov 07 2014
CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock Nov 07 2014
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock Nov 06 2014
CTI BIOPHARMA CORP Files SEC form 8-K/A, Financial Statements and Exhibits Nov 06 2014
CTI BIOPHARMA CORP Financials Nov 06 2014
10-Q for CTI BioPharma Corp. Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK